CDC42 and neoplasm: CDC42 displayed significantly reduced expression in tumor compared to normal samples, and lower CDC42 levels correlated with poorer survival outcomes, consistent with recent findings linking CDC42 dysregulation to aggressive cancer phenotypes (Justilien et al.